Novavax Inc. says that early data show its Covid-19 vaccine offers protection against the virus’ Omicron variant, though the Gaithersburg vaccine maker added that producing an Omicron-specific vaccine may still be necessary.
The company’s early trials showed that a two-dose regimen of its vaccine, called Nuvaxovid, prompted immune responses against the Omicron and other variants, and those immune responses increased after a third dose administered after three to six months, it said in a press release.
Novavax (NASDAQ: NVX) said that the three-dose regimen provoke a response against Omicron that was comparable to the response against the original virus demonstrated in its Phase 3 trials, when the vaccine was shown to be nearly 90% effective against all variants.
But neutralization of Omicron was “4-fold lower” than against the original variant in a two-dose regimen, “suggesting that both a booster dose as well as an Omicron-specific vaccine may be beneficial,” Novavax…
Read the full story from the Washington Business Journal.
